Home › Funds › PSP Research LLC › ALNY

PSP Research LLC position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

PSP Research LLC reported holding 1,465 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$441K, representing 0.23% of its reported portfolio and ranking #28 among its reported holdings. PSP Research LLC has disclosed ALNY holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)1.47K sh
Reported value held$441.01K
Portfolio Weight0.23%
First reportedQ4 2025
Last changeNew

How PSP Research LLC's ALNY position evolved

PSP Research LLC first disclosed a stake in ALNY in Q4 2025 at 1,318 shares (US$524K). Across 3 filings, PSP Research LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,465 shares valued at US$441K.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.32K $524.10K New
Q1 2026 1.47K $484.73K Add
Q2 2026 1.47K $441.01K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →